Rovi granted patent for schizophrenia injectable depot composition
Summary
USPTO granted patent US12594236B2 to Laboratorios Farmaceuticos Rovi, S.A. for a method of treating acute exacerbation of schizophrenia using a long-acting injectable depot composition containing risperidone. The patent covers a formulation achieving substantial PANSS score reduction within eight days and lasting up to four weeks without requiring loading doses or oral supplementation. The patent has 23 claims and was filed May 18, 2022 under application No. 17747422.
What changed
USPTO granted patent US12594236B2 to Laboratorios Farmaceuticos Rovi, S.A. covering a method of treating acute exacerbation of schizophrenia via intramuscular administration of a long-acting injectable depot composition containing risperidone. The method provides reduction in PANSS (positive and negative scales) and CGI-S scores within approximately eight days after administration and for up to at least four weeks. The patented method does not require loading doses of risperidone or supplementation with oral risperidone after administration.
This is a routine patent grant that establishes intellectual property rights for the assignee. Competitors developing similar long-acting injectable formulations for schizophrenia treatment should review the claims to assess potential infringement risk. No compliance deadlines, reporting requirements, or penalties are associated with this patent grant.
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
Grant US12594236B2 Kind: B2 Apr 07, 2026
Assignee
LABORATORIOS FARMACEUTICOS ROVI, S.A.
Inventors
Ibon Gutierro Aduriz, Guillermo Franco Rodriguez
Abstract
A method of treating an episode of acute exacerbation of schizophrenia by intramuscular administration of a long-acting injectable depot composition containing risperidone is provided. The method provides a substantial reduction in PANSS (both positive and negative scales) and CGI-S scores within about eight days after administration of the composition and for up to at least four weeks. The method is used to treat a subject suffering a first-time episode of or a relapse of severe to moderate symptoms associated with schizophrenia. The method does not require loading doses of risperidone in the depot composition and does not require supplementation with oral risperidone after administration of the depot composition.
CPC Classifications
A61K 31/519 A61K 9/0019 A61K 9/0024 A61K 47/20 A61K 47/34 A61K 24/20 A61K 24/34 A61P 25/18
Filing Date
2022-05-18
Application No.
17747422
Claims
23
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.